Clinical Trials Logo

Clinical Trial Summary

The current recommendations for dietary amino acid intake in pregnant women are based on calculations from requirements of adult men. The study aims to determine methionine requirements during early (11-20 weeks) and late (31-38 weeks) stages of pregnancy. Methionine, an essential amino acid (building block of body protein), is necessary for protein synthesis and for DNA related cellular functions. A non-invasive, novel method based on different diets, stable isotopes (the safe kind) and simple breath collection will be used. This method has recently been used by our laboratory to study other amino acids during pregnancy.

Clinical Trial Description

Pre-study day protocol:

Participants will be asked to meet for a brief (1 hour) pre-study assessment in preparation for the study day. Participants' eligibility will be assessed during this time. Subjects will arrive at the British Columbia Children's Hospital Research Institute's Clinical Research and Evaluation Unit (CREU) having fasted overnight (at least 8 hours since last caloric intake; no morning exercise, and assisted transportation to minimize stress). The consent form will be thoroughly explained, with the subject instructed to stop and ask questions at any point in which they are confused or uncomfortable. If the participants are willing to participate, verbal consent and a signature will be obtained. On this day, participants will fill out a questionnaire, and the following measurements will be taken: height (Harpenden Stadiometer; Holtain Limited, UK) and weight (electric scale; HealthOMeter Professional, Sunbeam Products, Inc.), bioelectrical impedance analysis (BIA; Q4 Bioimpedance Analyzer, RJL Systems, MI), 3 site skinfold (Harpenden Calipers; Baty International, UK), blood glucose (One Touch Ultra, LifeScan, Inc.), and resting energy expenditure (REE; Vmax Encore, Viasys, CA). The REE describes the caloric requirement for vital function in the absence of physical exertion. This value will be used to calculate the total energy content of the experimental diets in order to ensure that the specific caloric needs of each participant will be met. Blood glucose will be assessed for gestational diabetes mellitus (GDM; fasting plasma glucose level of 5.3 mmol/L indicative of GDM). Skinfold and BIA measurements will be collected to determine maternal fat and fat free mass.

Study day protocol:

Healthy pregnant women (20-40 y) who have consented and participated in the pre-study day will be studied at two stages of gestation (n=15/stage) over a range of test methionine intakes (ranging from 0-40mg/kg/day). At the beginning and end of the day a urine dipstick test will be performed. Each study day will be separated by a week and will receive a different, random methionine test intake. On the day of the study, participants will come in fasted at ~8 am for a total of eight hours. They will receive eight hourly meals, which represent 1/12 of their balanced nutritional need for the day. The meals consist of an orange flavoured shake with egg protein composition, balanced with sufficient carbohydrates and lipids. A tracer amino acid (L-[1-13C] phenylalanine) will be provided with the test meals to assess oxidation of the tracer to 13CO2 (13C- carbon dioxide) in breath in response to the test/limiting amino acid (methionine). Open-circuit indirect calorimetry will be performed until 5 steady state data points will be obtained for the measurement of VCO2 (Carbon Dioxide Output; Vmax Encore, Viasys, CA). This technique, called the indicator amino acid oxidation method, is a novel, non-invasive and completely safe approach especially in pregnancy.

Throughout the 8-hour study period biological samples (breath, urine, blood) will be collected and analyzed for 13CO2 content and sulfur amino acid metabolites. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04326322
Study type Interventional
Source University of British Columbia
Contact Rajavel Elango, PhD
Phone 6048752000
Email [email protected]
Status Recruiting
Phase N/A
Start date September 14, 2020
Completion date December 2021

See also
  Status Clinical Trial Phase
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT03911739 - Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study Phase 3
Completed NCT03188250 - Chama Cha MamaToto: a Pilot Study of Peer Support Groups in Kenya N/A
Recruiting NCT03671109 - Improving Maternal heAlth by Reducing Malaria in African HIV Women Phase 3
Recruiting NCT03855735 - Communication and Patient Safety in Gynecology and Obstetrics - Study Protocol of an Intervention Study N/A
Active, not recruiting NCT03679130 - FitMum: Fitness for Good Health of Mother and Child N/A
Completed NCT03687879 - Women's Evaluation of the Childbirth Experience: From Pregnancy to Postpartum
Recruiting NCT04568044 - Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
Recruiting NCT04572178 - Cash Payment and Counseling During Pregnancy N/A
Recruiting NCT04079959 - Endometrial Leucocytes Around the Time of Embryo Implantation in Women Undergoing in IVF-ET
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Completed NCT04146025 - Nurtured in Nature N/A
Recruiting NCT04918524 - The Clinical Features and Pregnancy Outcomes of CTD Patients
Not yet recruiting NCT04925765 - Virtual Reality Biofeedback for Postpartum Anxiety and Depression N/A
Recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Not yet recruiting NCT04350554 - Pregnancy in Women With HIV Infection
Not yet recruiting NCT04404231 - Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation N/A
Not yet recruiting NCT04214223 - Conception of a Decisional Tool Using a Pre-Anesthesic Numerical Evaluation (PANE) During the 8th Month of Pregnancy